journal
https://read.qxmd.com/read/38477323/immune-checkpoint-inhibitor-induced-inflammatory-arthritis-overview-of-therapies-and-a-personalized-approach-to-optimized-combined-therapy
#1
JOURNAL ARTICLE
Noa Rose, Victoria Furer, Ari Polachek, Ori Elkayam, Smadar Gertel
Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4, anti-programmed cell death 1, and anti-programmed cell death ligand 1 (PD-L1) antibodies, are currently widely used in oncology clinical practice, achieving considerable success in improving disease outcomes. New checkpoint targets are being discovered and investigated through basic science research and clinical trials. ICI remove negative regulatory immune signals on T cells, leading to immune activation and induction of antitumor immunity...
January 11, 2024: European Journal of Rheumatology
https://read.qxmd.com/read/38015122/senescence-in-osteoarthritis-overview-of-mechanisms-and-therapeutics
#2
JOURNAL ARTICLE
Natalya Surmachevska, Jose Rubio
Osteoarthritis is a morbid and costly condition affecting an increasingly larger segment of the population with a lack of effective treatment options. The pathophysiology of osteoarthritis is poorly understood; cell senescence is deemed to be contributory. Senescence of joint tissues particularly chondrocytes, synoviocytes (fibroblasts), and adipocytes is implicated in the pathogenesis through the production of senescence-associated proteins. Senescence-associated proteins are cytokines, matrix degradation enzymes, and chemokines that contribute to an inflammatory milieu which leads to the propagation of senescence...
November 28, 2023: European Journal of Rheumatology
https://read.qxmd.com/read/38015121/surgical-treatments-for-osteoarthritis
#3
JOURNAL ARTICLE
Ilana Usiskin
Osteoarthritis is a prevalent and disabling condition most commonly affecting the knees, hips, and hands. Since there are currently no disease-modifying therapies available, patients with persistent pain and functional impairment despite pharmacologic and other non-operative therapies should be considered for surgical management. For both knee and hip Osteoarthritis, the most common surgical approach is total joint arthroplasty, an elective surgical procedure that generally has favorable outcomes with most patients reporting significant improvements in pain, function, and quality of life...
November 28, 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37873666/influenza-vaccine-type-dependent-antibody-response-in-patients-with-autoimmune-inflammatory-rheumatic-diseases
#4
JOURNAL ARTICLE
Sofie Larsen Rasmussen, Prabhat Kumar, Ramona Trebbien, Peter Leutscher, Claus Rasmussen
BACKGROUND: The study aimed to explore influenza antibody response in patients with autoimmune inflammatory rheumatoid diseases (AIIRDs) stratified by the different vaccine types applied in Denmark during the 2018-2019 influenza season. METHODS: Included patients were diagnosed with rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis receiving biological disease-modifying antirheumatic drugs (bDMARDs) with or without conventional synthetic disease-modifying antirheumatic drugs...
October 24, 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37850605/comparative-metabolomic-profiles-of-vascular-involvement-in-beh%C3%A3-et-s-disease
#5
JOURNAL ARTICLE
Çiğdem Yücel, Erdim Sertoğlu, Ahmet Omma, Engin Koçak, Sevilay Erdoğan Kablan, Taner Özgürtaş, Emirhan Nemutlu
BACKGROUND: Behçet's disease is a systemic, inflammatory disease affecting multiple organs. Vascular involvement is the main cause of morbidity and mortality in Behçet's disease patients. Though clinically well-defined, there is limited information related to disease pathogenesis and vascular incidence in this patient group. The aim of this study is to investigate the unique metabolic signatures of Behçet's disease patients with vascular involvement. METHODS: Metabolomic profiling was performed on serum samples of 48 Behçet's disease patients (18 with vascular involvement) and 40 healthy controls using gas chromatography-mass spectrometrybased untargeted metabolomics analysis...
October 18, 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37885267/thrombocytopenia-in-patients-with-systemic-lupus-erythematosus
#6
JOURNAL ARTICLE
Omer Nuri Pamuk
Thrombocytopenia can be one of the first manifestations of systemic lupus erythematosus and occurs in up to 40% of patients. Additionally, approximately 2% of patients with primary immune thrombocytopenia may develop systemic lupus erythematosus. Systemic lupus erythematosus is a highly heterogeneous disease, and in some patients, it may present mainly with hematological findings. Thrombocytopenia associated with systemic lupus erythematosus is also diverse, ranging from asymptomatic to severe, acute, or chronic cases...
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37885266/coronavirus-disease-2019-in-rheumatic-patients-with-inflammatory-disorders-a-descriptive-study-from-a-high-infection-incidence-region-of-northern-spain
#7
JOURNAL ARTICLE
Orlando Pompei Fernández, Paula García Escudero, Marta González Fernández, Claudia Stoye, César Antonio Egües, Jose Francisco García Llorente, Itziar Calvo Zorrilla, Oihane Ibargüengoitia Barrena, Ana Ruibal-Escribano, Juan Ramón De Dios, Joaquín María Belzunegui Otano, Belén Álvarez Rodríguez, Susana Gil Barato, Elena Garmendia Sánchez, Margarida Vasques Rocha, Edurne Guerrero, Jaime Calvo-Alén
BACKGROUND: Since the first confirmed case of severe acute respiratory syndrome coronavirus 2 in Spain in January 2020, the susceptibility of patients with rheumatic disease has remained unclear. In this report, we will describe the main features of coronavirus disease 2019 (COVID-19) that occurred in rheumatic patients with inflammatory disorders and try to identify features associated with severe disease. METHODS: We included all rheumatic patients with immune-mediated diseases followed at 6 centers belonging to the public healthcare system in the Basque Country (Spain) and diagnosed with COVID-19 from March 1, 2020, to May 31, 2020...
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37873667/immunoglobulin-g4-related-lesions-in-autoimmune-diseases-unusual-presentations-at-atypical-sites-a-tale-of-2-cases-with-literature-review
#8
JOURNAL ARTICLE
Ritasman Baisya, Keerthi Vardhan Yerram, Arun Baby, Phani Kumar Devarasetti, Liza Rajasekhar
Immunoglobulin G4-related disease (IgG4-RD) coexisting with clinically apparent autoimmune diseases, such as rheumatoid arthritis (RA) or antiphospholipid syndrome (APS), is a rarely documented combination in the scientific literature. In this case-based review, we present 2 intriguing cases with preexisting autoimmune diseases, namely, RA and primary APS, who exhibited coexistent IgG4- related lesions at unusual sites. The first case pertains to a patient with known RA who presented with an encasing mass in the esophagus leading to stricture, with histopathological diagnosis of IgG4-RD...
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37873665/resveratrol-in-rheumatological-diseases-a-systematic-review
#9
JOURNAL ARTICLE
Jozélio Freire de Carvalho, Aaron Lerner
Resveratrol is an antioxidant with anti-inflammatory and cell-protective properties. The aim of our article is to review the use of resveratrol in rheumatic diseases. PubMed/Medline, Embase, and Scielo were screened for articles on resveratrol and rheumatic diseases in the period between of January 1966 and March 2023. Five articles were depicted, including 481 patients. The included diseases were osteoarthritis (n=3), rheumatoid arthritis (n=1), and Takayasu arteritis (n=1). The age varied from 32 to 58.2 years, and the female gender ranged from 62% to 74% in the studies...
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37850609/infections-in-patients-with-systemic-lupus-erythematosus-the-contribution-of-primary-immune-defects-versus-treatment-induced-immunosuppression
#10
JOURNAL ARTICLE
Ana Laura Fischer Kunzler, George C Tsokos
Patients with systemic lupus erythematosus experience high rates of infections. The use of immunosuppressive drugs to treat the disease, along with the fact that both the innate and adaptive branches of the immune system are compromised, account for the development of infections. In this communication, we briefly discuss the aberrant function of the immune system in patients with systemic lupus erythematosus and review the occurrence of infections that have been reported in clinical trials conducted to develop new therapeutics...
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37850608/positive-prayer-sign-in-tophaceous-gout
#11
JOURNAL ARTICLE
Sadettin Uslu
No abstract text is available yet for this article.
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37850607/neuropsychiatric-manifestations-in-systemic-lupus-erythematosus-patients-at-a-tertiary-hospital-in-peru
#12
JOURNAL ARTICLE
Jose Camones-Huerta, Christian Arias-Osorio, Diana Rodriguez-Hurtado, Jose Aguilar-Olano
BACKGROUND: Systemic lupus erythematosus is a prevalent autoimmune disease that affects multiples systems, exerting its most incapacitating and life-threatening impact through neuropsychiatric involvement. According to the American College of Rheumatology (ACR), 19 neuropsychiatric syndromes types of SLE are classified into categories encompassing the central and peripheral nervous systems. This study aimed to investigate the frequency of neuropsychiatric manifestations in systemic lupus erythematosus patients admitted to Hospital Cayetano Heredia in Lima, Peru, between 2008 and 2019...
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37850606/a-tangled-autoimmune-trio-multiple-sclerosis-systemic-lupus-erythematosus-and-antineutrophil-cytoplasmic-antineutrophil-cytoplasmic-antibody-vasculitis
#13
JOURNAL ARTICLE
Rajaie Namas, Sarah Al Qassimi, Muriel Ghosn, Esat Memisoglu, Ahmad Alduaij, Leal Herlitz, Victoria A Mifsud
The coexistence of multiple autoimmune diseases in the same individual is unusual and has received little attention in the literature. We present a young female patient with multiple sclerosis, systemic lupus erythematosus, and biopsy-proven renal proteinase 3 antineutrophil cytoplasmic antibodyassociated vasculitis who responded well to intravenous rituximab clinically and serologically.
October 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37594394/the-relationship-between-sarcopenic-obesity-and-knee-osteoarthritis-the-sarcob-study
#14
JOURNAL ARTICLE
Sarah Razaq, Murat Kara, Levent Özçakar
BACKGROUND: To investigate whether sarcopenic obesity may contribute to knee osteoarthritis or not. METHODS: In this study, we assessed 140 community-dwelling adult patients. Their demographic data were recorded along with comorbidities. Anterior mid-thigh muscle thickness in the axial plane was measured on the dominant leg using ultrasound midway between the anterior superior iliac spine and the upper end of patella in millimeter. Then, the sonographic thigh adjustment ratio was calcu- lated by dividing this thickness by body mass index...
August 18, 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37594393/prediction-of-response-to-treatment-using-doppler-signal-positivity-measured-by-ultrasound-in-rheumatoid-arthritis-a-proof-of-concept-study
#15
JOURNAL ARTICLE
Ummugulsum Gazel, Gizem Ayan, Dilek Solmaz, Nancy Maltez, Tim Ramsay, Antonio R Cabral, Servet Akar, Sibel Zehra Aydin
No abstract text is available yet for this article.
August 18, 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37681259/after-ultrasound-blind-injections-relics-of-musculoskeletal-medicine-or-lack-thereof
#16
JOURNAL ARTICLE
Levend Karaçoban, Levent Özçakar
No abstract text is available yet for this article.
July 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37681258/sweet-syndrome-of-the-hands
#17
JOURNAL ARTICLE
Irene Arevalo Ortega, Mikel Meruelo Ruano, Nekane Martinez Peña, Isabel Gainza Apraiz, Ane Lobato Izagirre
No abstract text is available yet for this article.
July 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37681257/tomographic-fibrosis-score-in-the-patients-with-systemic-sclerosis-associated-interstitial-lung-disease
#18
JOURNAL ARTICLE
Mustafa Ozmen, Cesur Gumus, Eda Otman, Kazim Ayberk Sinci, Idil Kurut Aysin, Dilek Solmaz, Servet Akar
BACKGROUND: Various visual semi-quantitative staging systems based on high-resolution computed tomography are used to evaluate inflammatory rheumatologic disease-associated interstitial lung disease. We aimed in this retrospective study to evaluate whether tomographic fibrosis score, a new visual semi-quantitative staging system, was a predictor of mortality and the relationship between tomographic fibrosis score and respiratory function tests in patients with systemic sclerosis-associ- ated interstitial lung disease...
July 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37681256/matrix-metalloproteinase-2-and-3-levels-in-patients-with-beh%C3%A3-et-s-disease-and-implication-for-the-presence-of-vascular-aneurysm-or-neurologic-involvement
#19
JOURNAL ARTICLE
Pinar Talu Erten, Gökhan Keser, Raika Durusoy, Sinem Burcu Kocaer, Kenan Aksu
BACKGROUND: Behçet's disease is a systemic vasculitis affecting both arteries and veins, as well as caus- ing recurrent inflammatory multiorgan disease. Vascular involvement is associated with increased mortality and morbidity. Matrix metalloproteinases are released at sites of inflammation and degrade various components of the extracellular matrix. Increased levels of metalloproteinase-9 and metal- loproteinase-2 have been previously reported in Behçet's disease. METHODS: In this cross-sectional study, metalloproteinase-2 and metalloproteinase-3 serum levels were investigated in 103 patients with Behçet's disease and 69 healthy controls, using Invitrogen immunoassay human metalloproteinase-2 and metalloproteinase-3 ELISA kits...
July 2023: European Journal of Rheumatology
https://read.qxmd.com/read/37681255/glucocorticoid-induced-osteoporosis-increased-awareness-as-a-management-strategy-for-prevention-of-this-complication-in-patients-with-systemic-autoimmune-rheumatic-disease
#20
JOURNAL ARTICLE
Adegbenga Bankole, Emma L Greear
BACKGROUND: It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and oth- ers for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporosis and an increase in the risk of fractures. The increased risk is related to both the daily dose and the cumulative dose of the glucocorticoids. Despite the availability of effective preventative and treatment options, glucocorticoid-induced osteoporosis is often not mitigated with the use of these preventive therapies...
July 2023: European Journal of Rheumatology
journal
journal
53750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.